Synonym
Propericiazine; Periciazine; Propericiazine; PERICYAZINE; Neuleptil; Piperocyanomazine; Aolept; Aolept; Neuleptil; Neuleptyl; periciazine; pericyazine;
IUPAC/Chemical Name
10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
InChi Key
LUALIOATIOESLM-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
SMILES Code
C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
365.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ikeda H, Tsuji E, Matsubara T, Yukawa M, Fujisawa M, Yukawa E, Aki H.
Incompatibility between propericiazine oral solution and tea-based drink. Chem
Pharm Bull (Tokyo). 2012;60(9):1207-11. PubMed PMID: 22976331.
2: Cechin EM, Quevedo J, Barichello T, Machado-Vieira R, Gentil V, Kapczinski F.
Dose-related effects of propericiazine in rats. Braz J Med Biol Res. 2003
Feb;36(2):227-31. Epub 2003 Jan 29. PubMed PMID: 12563525.
3: Ananth JV, Ban TA. A standard-controlled clinical study with propericiazine in
schizophrenic patients. Psychopharmacol Bull. 1977 Jul;13(3):19-20. PubMed PMID:
18754.
4: Ananth JV, Salib M, Ban TA, Lehmann HE. Propericiazine in psychiatric
emergencies. A controlled comparative study. Can Psychiatr Assoc J. 1972
Apr;17(2):143-5. PubMed PMID: 4402542.
5: Ropert R, Levy L, Bouyssou V, Ropert M. [Use of high doses of a major
neuroleptic, propericiazine, in the treatment of psychotic syndromes]. Encephale.
1970 Sep-Oct;59(5):460-78. French. PubMed PMID: 4396004.
6: Lazzaroni Fossati F, Podestà F, Duillo MT. [A case of acute poisoning with
propericiazine in a pediatric patient]. J Econ Entomol. 1970 Aug;63(4):1077-83.
Italian. PubMed PMID: 4395165.
7: Seebandt G. [Experiences with propericiazine in the treatment of functional
psychomotor disorders and states of restlessness in childhood].
Arzneimittelforschung. 1970 Jul;20(7):937-9. German. PubMed PMID: 4394249.
8: Lazzaroni Fossati F, Podestà F, Duillo MT. [A case of acute poisoning with
propericiazine in a pediatric patient]. Minerva Pediatr. 1970 May
26;22(21):1077-83. Italian. PubMed PMID: 4395639.
9: Agostinis G, Porati U, Maifreni F. [Critical review of the pharmacological
action of propericiazine in infantile preanesthesia. (Statistical study of 2075
cases)]. Acta Anaesthesiol. 1970;31:Suppl:167-75. Italian. PubMed PMID: 4398517.
10: Giménez Roldán S, Campos Castelló J. [Propericiazine and behavior disorders
in neurological diseases in childhood and adolescence]. Arch Neurobiol (Madr).
1969 Jul-Sep;32(3):331-46. Spanish. PubMed PMID: 4392861.
11: Sacerdote I, Nivoli GC. [Clinical observations on the use of propericiazine
in states of post-traumatic psychomotor agitation]. G Psichiatr Neuropatol.
1969;97(2):351-6. Italian. PubMed PMID: 4391569.
12: Dostál T. [Treatment of oligophrenic children and adolescents with
propericiazine]. Act Nerv Super (Praha). 1968 Oct 3;10(3):319. German. PubMed
PMID: 4387432.
13: Haase HJ, Deinzer C, Rhinow E. [Clinico-neuroleptic studies of the
neuroleptic agent Propericiazine with special consideration of the neuroleptic
threshold]. Med Welt. 1968 Jul 6;27:1580-4. German. PubMed PMID: 4388432.
14: Ronco P, Mezzena G, Priora PM. [Effect of propericiazine (Neuleptil) on the
Rorschach psychodiagnostic test in children during differential treatment].
Minerva Med. 1968 Jul 4;59(53):3003-7. Italian. PubMed PMID: 4386141.
15: Ronco P, Davy M. [Psychological changes during propericiazine (Neuleptil)
treatment of adolescents with scholastic adaptation difficulties]. Minerva Med.
1968 May 19;59(40):2357-64. Italian. PubMed PMID: 5653334.
16: Steinecker G, Schirardin H, Métais P. [Distribution and metabolism of
phenothiazines. II. Experimental study in the rat of propericiazine and
fluphenazine in toxic doses. Comparison with chlorpromazine]. Ann Pharm Fr. 1968
Feb;26(2):143-52. French. PubMed PMID: 4387792.
17: De Gregorio G, Frascella G, Logoluso R. [Clinical and EEG findings in
patients with character disorders treated with propericiazine]. Acta Neurol
(Napoli). 1968 Jan-Feb;23(1):238-40. Italian. PubMed PMID: 4391513.
18: Proto A, Gentilucci C. [Clinical experience with propericiazine or an
adjuvant in the therapy of epileptic syndromes]. G Psichiatr Neuropatol.
1968;96(4):819-33. Italian. PubMed PMID: 4391103.
19: Nardini L, Pistoni A. [Selectivity of action of propericiazine in behavior
disorders]. Riv Sper Freniatr Med Leg Alien Ment. 1967 Apr 3;91(2):569-75.
Italian. PubMed PMID: 4384082.
20: Ferguson K, Ban TA, Lehmann HE, Lee H. [A comparative study of propericiazine
in the management of antisocial behavior]. Union Med Can. 1967 Apr;96(4):448-9.
French. PubMed PMID: 4382825.
